In Brief: Collagen
This article was originally published in The Gray Sheet
Collagen: Plans to spin off its Collagen Technologies R&D business to Collagen shareholders by spring 1998, David Foster, senior VP and general manager of Collagen Technologies Group, stated at an Oct. 27 session of the Oppenheimer conference. Collagen announced plans to separate the operations from Collagen's Aesthetic Technologies businesses in January ("The Gray Sheet" Jan. 13, I&W-4)...
You may also be interested in...
Separate concerns raised by the EMA over bioequivalence studies have led Mylan and Accord to withdraw generic applications, including the former’s generic version of Gilenya for the treatment of multiple sclerosis.
New York's Avista Capital Partners has taken a 50% stake in Belgian consumer health player Vision Healthcare, which has its sights set on the US market.
Sun Pharma says that the first quarter of financial 2021 will likely be challenging across the industry with a lull in new prescriptions in India, especially in the acute and semi-chronic segments. But the firm remains upbeat about its lead psoriasis asset Ilumya, which has inched close to the $100m sales mark in its first full year of commercialization.